Invest
27 Years
4.4 Star
1 Crore +
Pharmaceuticals company Neuland Laboratories announced Q4FY24 & FY24 results:
- FY24 income at Rs 1,571.1 crore, up 30.8% YoY
- EBITDA at Rs 474.5 crore, up 68.8% YoY
Commenting on the performance Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “We surpassed revenues of Rs 1,500 crore in FY24 with EBITDA at over 30%. This has been driven by high growth in the CMS business and steady growth of the Specialty GDS business, both of which were in line with our plans and expectations. Another key element is the work on optimizing costs & processes which will also make us truly sustainable.”
In addition, Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added “Our CMS business saw robust growth in FY24 as some projects are near launch while key commercial products continue to scale. Our growing reputation and the macro-environment are ensuring that exciting opportunities come our way even as we work towards building a further differentiated customer experience. We will continue to invest for the future by adding capacity and capabilities.”
FAQ’s on Neuland Laboratories Ltd Shares
